Considerations for a business model for the effective integration of novel biomarkers into drug development

MLA

Felix W Frueh. “Considerations for a Business Model for the Effective Integration of Novel Biomarkers into Drug Development.” Personalized Medicine, vol. 5, no. 6, May 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d8d21a50e09e9ca622e95e764c805acd&authtype=sso&custid=ns315887.

APA

Felix W Frueh. (2018). Considerations for a business model for the effective integration of novel biomarkers into drug development. Personalized Medicine, 5(6).

Chicago

Felix W Frueh. 2018. “Considerations for a Business Model for the Effective Integration of Novel Biomarkers into Drug Development.” Personalized Medicine 5 (6). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d8d21a50e09e9ca622e95e764c805acd&authtype=sso&custid=ns315887.